Background: Treatment for allergic rhinitis (AR) aims at reducing the burden of allergic inflammation, either by suppression of the nasal inflammation with pharmacotherapy or by inducing tolerance via immunotherapy (IT). At present, we lack information on the comparison between the degree of symptom control in AR patients treated with IT and those on pharmacotherapy.
Introduction
Pharmacotherapy for allergic rhinitis (AR) aims at reducing the burden of allergic inflammation, either by the suppression of the nasal and systemic symptoms associated with AR, or by the induction of tolerance to the allergens (1) . Different types of molecules like antihistamines, corticosteroids and leukotriene antagonists have anti-inflammatory properties and are recommended in international guidelines for the treatment of AR (2) . The nasal or oral routes of administration are chosen by the clinician mainly on the base of expected benefit and clinical phenotype of AR. According to a survey of Cornelis et al. sublingual immunotherapy is the most frequently used form of IT in Belgium (3) . The induction of tolerance is the goal of allergen-specific immuno-therapy (IT), being administered via the subcutaneous (SCIT), sublingual (SLIT) or oral route (3) . Tolerance to the inhalant allergens is obtained by the induction of regulatory T lymphocytes and a deviation of the immune response away from the so-called T helper 2 cytokine profile (5) . Nasal provocation results in an increase in eosinophils in the nasal mucosa, but Muller et al. showed no change in the number of FoxP3 + CD4 + cells in a mono-or multiple-sensitized GP allergic individual, so the stronger clinical response to nasal provocation with GP is not related to differences in the number of regulatory T cells in the nasal mucosa (6) . SCIT has been the standard IT modality since decades, with recent demonstration of efficacy of sublingual (4) and oral forms of IT (3) .
Pharmacotherapy as well as IT have both been proven to be effective on the level of symptom reduction as well as on inflammatory parameters like cytokine levels and histology scores in AR (1) . The decision to prescribe pharmacotherapy or start with IT for AR is multi-factorial, involving the clinical phenotype of the patient, the sensitization profile of the patient, the degree of efficacy and/or tolerability of pharmacotherapy, as well as the overall perceived severity of the nasal and general symptoms.
Prior to starting treatment, the expected benefits of pharmacotherapy and IT are ideally discussed with patients, as each treatment modality has its intrinsic advantages (5) . Until recently, we did not have good tools for the evaluation of symptom control in AR. Bousquet et al. were the first to demonstrate that a VAS score for TNS correlated well with the validated and widely used Rhinoconjunctivitis Quality of Life Questionniare (6) , hence offering the clinicians a convenient tool to use in clinical practice.
In addition, Demoly et al. developed an allergic rhinitis control test (ARCT), which also is clinically applicable but more complex than the VAS for TNS ) (7) .
At present, we lack information on the comparison of the degree of symptom control between patients on pharmacotherapy and those on IT. Therefore, we conducted an observational study evaluating the degree of symptom control using the VAS for TNS in the patient population that had been started on either pharmacotherapy or IT 3 years prior to the study. Beside the VAS for TNS, other clinically important parameters like severity and duration of symptoms and medication use were assessed. Only patients who were really been treated for three years were included, so since the survey was conducted between October and February 2013, we used a variability of 4 months.
Materials and methods

Study population
Inclusion criteria included all of the following items: having an age between 16 and 65 years old, being diagnosed with AR on the base of two symptoms suggestive of AR (sneezing, pruritus, nasal congestion and/or rhinorrea) and a positive SPT for at least one of the 18 most common inhalant allergens in Belgium (house dust mites, 7 different grass pollen, 3 kinds of tree pollen, animal dander (dog, cat, horse, rabbit), Alternaria, Penicillium and Cladosporium (HAL Allergy, Leiden, The Netherlands)). A positive SPT was defined by a wheal reaction of at least 3 mm in diameter or of a size equal to or larger than the positive control (histamine) after 15 min, as recommended by Scadding, Hellings, Alobid, Bachert, Fokkens, van Wijk, et al. (8) .
All included patients had been diagnosed with moderate-tosevere and/or persistent AR, as defined by the ARIA guidelines (2) , and rhinosinusitis and/or nasal anatomic pathology had been excluded by nasal endoscopy performed at the outpatient ENT clinic.
In all AR patients, pharmacotherapy was started as advocated in the ARIA guidelines (9) , unless they met the following indications for starting subcutaneous IT: year.
-The current medication use at the time of evaluation, asking to specify the current treatment e.g. type of spray, or tablet, combination treatment or IT. Patients that had been started on IT were asked if the IT was still ongoing or finalized.
The Ethical Committee of the University Hospitals of KU Leuven approved the study protocol.
Statistical analysis
Descriptive statistics included frequencies and mean values. D'agostino and Pearson omnibus normality test was performed on data in both IT (median 1.9, interquartile range 0.7 -3.4) and control group (median 3.2, interquartile range 1.5 -6.1) and showed a nongaussian distribution (p-value = 0.0001). Patients belonging to the non-IT group, reporting current or past IT, were excluded from the study, since the non-IT group consists of patients treated with pharmacotherapy only.
Comparison of outcome parameters between the IT and the
During the treatment with IT, patients were allowed to use pharmacotherapy as add-on treatment depending on their symptoms. In the non-IT group, patients only used pharmacotherapy depending on their symptoms. We did not look for medication use during those 3 years, but only after 3 years, depending on their symptoms.
Questionnaires
The questionnaires were sent to all AR patients included in this study involving the following issues: -A VAS score of 0-10 was used to measure each of TNS, i.e. nasal symptoms in general, we asked for any nasal complaint they suffered from, and individual nasal symptoms, i.e. nasal congestion, rhinorrhoea, sneezing, pruritus, headaches, reduction of sense of smell, cough, dyspnea and wheezing, experienced during the last 4 weeks. Visual analogue scales (VAS) have been used to rate the presence of symptoms or impairment of the daily activities (10) . Bousquet et al. proposed this simple method for the quantitative evaluation of severity of AR, with a cut off value to distinguish between controlled (<5) and uncontrolled AR (≥ 5) (6) .
-Presence or absence of abnormal sleep, impairment of daily activities, sport, leisure, impaired functioning at work/school and troublesome symptoms, to distinguish between mild i.e. none of the above symptom, or moderate/severe, i.e. at least one of the symptoms had to be present, AR.
-Duration of nasal symptoms, persistent, i.e. more than 4 days a week, and more than 4 consecutive weeks a year, intermittent i.e. less than 4 days a week and less than 4 consecutive weeks a 
Degree of control of rhinitis at a mean interval of 3 years after start of therapy
Control is defined as a disease state in which the patients do not have major symptoms anymore or the remaining symptoms are not regarded as bothersome, with VAS scores for TNS being a good tool (10) . In the IT group, 84% of patients had a VAS for TNS of < 5, whereas this was lower in the non-IT group (63%, Figure   1A this was statistically lower in the non-IT group (63%, Figure 1A) (p-value < 0.0002). Of note, 2 of the 13 IT patients with a VAS for TNS of ≥ 5 suffered from asthma, with a VAS score ≥ 5/10 for shortness of breath and wheezing during the last four months ( Table 2) .
Severity and duration of rhinitis at a mean interval of 3 years after start of therapy
In the IT group, 15 patients (18%) versus 178 non-IT patients (51%) were considered as having a persistent rhinitis ( Figure 1B) .
Meaning that in the IT group statistically significant less patients The ARIA classification of AR is based on duration and severity of AR symptoms (2) . In the IT group, 15 patients (18%) versus 178 non-IT patients (51%) reported symptoms for ≥ 4 days a week and ≥ 4 consecutive weeks per year, and were categorized as having persistent rhinitis ( Figure 1B) .
Patients of the IT group with intermittent AR showed significantly lower mean VAS (2.02±1.9) scores for total nasal symptoms compared to patients with persistent symptoms (4.8± 2.6) (pvalue < 0.0001).
Significantly less patients in the IT group (22%) met ARIA criteria for moderate-to-severe AR versus 241 patients (68%) in the non-IT group (Figure 1C , p-value < 0.0001).
Comparison between the IT and non-IT groups showed a significant difference in the ARIA based severity and duration classification of the AR at 3 years after start of therapy (p-value < 0.0001).
After 3 years of treatment, significantly less IT-patients suffered from severe or persistent AR compared to the non-IT group (05, Figure 2A -B, p-value < 0.0001, Fisher's exact test)1B and C)).
Current medication use at 3 years after start of therapy
The IT group was subdivided in patients with ongoing IT (n=46) and finished IT (n=36). The current medication use at 3 years after diagnosis of AR in those two groups was compared to the non-IT group (Figure 3 ). In the IT group, 29.3% of the patients used ARIA-based medication, 1 patient used a decongestion nasal spray and 69.5% were not on any medical treatment. In the IT group, there was a significantly higher number of patients with no need for medical treatment compared to the non-IT group (70% vs 39%) (p-value < 0.0001).
Sixty
Discussion
A meta-analysis performed by Cingi et al. in 2014 suggests that IT is associated with a much higher reduction of symptoms compared to placebo (14) . At present, we lack information on the comparison between the degree of symptom control of AR by pharmacotherapy and IT on the long term. Anotherin a real life setting. A meta-analysis performed by Matricardi et al. in 2011 provided indirect but consistent evidence that SCIT is at least as potent as pharmacotherapy in controlling the symptoms of seasonal AR as early as the first season of treatment (11) . We here make a first attempt to evaluate the degree of symptom control, the total and individual nasal symptom severity and the current medication use in patients at 3 years after either starting medical treatment or immunotherapy. IT was associated with a higher percentage of patients with controlled AR, with mild disease and with lower medication use than those AR patients in which IT was started or ongoing. The strength of this study lies inrelates to the real-life character of AR treatment in a tertiary referral center, as well as in the large number of patients studied in this monocenter trial. The authors acknowledge that non-responder bias may be a problem in survey studies. We tried to minimalize the non-responder bias by calling all the 54 patients who after two months didn't reply on the questionnaire initially. There were 28 of the non-responders (52%) who fulfilled the questionnaire after the telephone call.
Seven of them (25%) had a VAS ≥5. Overall mean VAS score of the initial non-responders was 3.1. There were only few (only 9 out of 120 patients) who refused to reply because of dissatisfaction about the treatment.
Of note, the questionnaire was filled out during the Fall season, Based on the proposed cut-off value of VAS < 5/10 for TNS (6) , rhinitis was considered as being controlled in 84% of IT patients vs 63% of non-IT patients. Amongst the uncontrolled patients in the IT group (13/82), 2 suffered from concomitant asthma.
For the TNS and the individual nasal symptoms we used a VAS score as suggested by Bousquet (9) , we conducted our study in 2013, but a more recent study shows that objective measures of nasal obstruction, especially Peak Nasal Inspiratory Flow, can give useful information on aspects of the disease, different from those obtained from the patient`s perception, so this needs to be taken in consideration in examining the AR patients (16) .
At 3 years after starting the treatment, 78% of the IT group were considered to have a mild form of AR compared to 32% in the non-IT group, with 82% of the IT group having intermittent AR vs 49% in the non-IT group. This observation is the clinical result of the allergen tolerance induced by IT and concomitant reduced symptom severity and reduced need for medication.
Comparison of medication use at 3 years after starting IT or medical therapy showed that 89% of the patients who have finished the IT and 54% of the patients who were still treated with IT, did not use additional medication for AR. Strikingly, 31%
of the patients treated with immunotherapy did not use any medication for treatment of AR anymore. Therefore, more frequent consultations with increased adherence to medical treatment cannot explain the results in this study, as the majority of AR do not need medical treatment anymore at 3 years after starting IT.
Our real-life observational study shows that the majority of patients with IT for AR perform better at 3 years after the onset of IT than the non-IT patients, on the level of symptom control, severity of disease and medication use. These observations are of clinical value when discussing the benefit of IT on the longterm with AR patients.
